Floatz logo

Gm-K562/Leukemia Cell Vaccine

Acute Myeloid Leukemia

Dana-Farber Cancer InstitutevaccinePhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
59/ 100

Competitive context

374 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Daunorubicin
Shen yang
Phase 4BB
Idarubicine
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
ETOPOSIDE
Memorial Sloan Kettering Cancer Center
Phase 4BB
Mitoxantrone
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Gm-K562/Leukemia Cell Vaccine is also rated in:

Myelodysplastic Syndrome-Refractory Anemia With Excess BlastsDormant
CC
Indicative ·
47 / 100
View asset →
Chronic Myelomonocytic LeukemiaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →